Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Cited by 1 publication
References 13 publications
SummaryMany patients still have high blood pressure (BP) after treatment with angiotensin II type 1 (AT 1 ) receptor blockers (ARBs). We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. Sixty-four hypertensive patients who were treated with ARBs other than azilsartan and olmesartan were enrolled in this study. We randomly assigned patients to changeover from their prior ARBs to either azilsartan or olmesartan, and followed the patients for 3 months. Systolic BP (SBP) in the azilsartan group was significantly decreased at 3 months, and diastolic BP (DBP) and pulse rate (PR) in the olmesartan group showed significant reductions after 3 months. There were no significant differences in ΔSBP, ΔDBP, or ΔPR (Δ = the value at 3 months minus the value at 0 months) between the groups. Serum levels of creatinine (Cr), uric acid (UA), and potassium (K) in the azilsartan group significantly increased after 3 months. While the changes in Cr, UA, and K were within the respective normal ranges, ΔSBP was positively associated with ΔCr in the azilsartan group. In conclusion, there was no difference in the depressor effects of azilsartan and olmesartan, and there were no serious changes in biochemical parameters with azilsartan and olmesartan. (Int Heart J 2017; 58: 416-421) Key words: Blood pressure, Angiotensin II type 1 receptor blocker, Uric acid S even types of angiotensin II type 1 (AT 1 ) receptor blockers (ARBs) have been developed and are available for clinical use in Japan.1) ARBs is effective in the treatment of cardiovascular disorders, including hypertension and heart failure.1,2) ARBs have been reported to have class-specific (common) and moleculespecific (differential) effects in basic experimental studies. 3)We have proposed that small differences in the molecular structures of ARBs could lead to differences in their abilities to influence the AT 1 receptor. 3,4) Azilsartan is the newest ARB to be approved for clinical use in Japan, and has a significant blood pressure (BP)-lowering effect, although the next generation ARBs could be a significant breakthrough in the field of cardiovascular medicine. 5)Azilsartan medoxomil and azilsartan have been reported to have greater antihypertensive effects than other ARBs.6-9) Azilsartan has been shown to bind tightly to and dissociate slowly from AT 1 receptors.10) Therefore, we hypothesized that the depressor effect of azilsartan may be superior to those of other ARBs in patients with hypertension (HTN). In this study, we performed a changeover from their prior ARBs to azilsartan or olmesartan in patients with hypertension, and compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. MethodsStudy design: Sixty-four hypertensive patients who were treated with ARBs except for azilsartan and olmesartan were enrolled. We applied a changeover of ARBs, where patients were prospectively and randomly switched from their prior ARBs, except for azilsartan and ...
SummaryMany patients still have high blood pressure (BP) after treatment with angiotensin II type 1 (AT 1 ) receptor blockers (ARBs). We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. Sixty-four hypertensive patients who were treated with ARBs other than azilsartan and olmesartan were enrolled in this study. We randomly assigned patients to changeover from their prior ARBs to either azilsartan or olmesartan, and followed the patients for 3 months. Systolic BP (SBP) in the azilsartan group was significantly decreased at 3 months, and diastolic BP (DBP) and pulse rate (PR) in the olmesartan group showed significant reductions after 3 months. There were no significant differences in ΔSBP, ΔDBP, or ΔPR (Δ = the value at 3 months minus the value at 0 months) between the groups. Serum levels of creatinine (Cr), uric acid (UA), and potassium (K) in the azilsartan group significantly increased after 3 months. While the changes in Cr, UA, and K were within the respective normal ranges, ΔSBP was positively associated with ΔCr in the azilsartan group. In conclusion, there was no difference in the depressor effects of azilsartan and olmesartan, and there were no serious changes in biochemical parameters with azilsartan and olmesartan. (Int Heart J 2017; 58: 416-421) Key words: Blood pressure, Angiotensin II type 1 receptor blocker, Uric acid S even types of angiotensin II type 1 (AT 1 ) receptor blockers (ARBs) have been developed and are available for clinical use in Japan.1) ARBs is effective in the treatment of cardiovascular disorders, including hypertension and heart failure.1,2) ARBs have been reported to have class-specific (common) and moleculespecific (differential) effects in basic experimental studies. 3)We have proposed that small differences in the molecular structures of ARBs could lead to differences in their abilities to influence the AT 1 receptor. 3,4) Azilsartan is the newest ARB to be approved for clinical use in Japan, and has a significant blood pressure (BP)-lowering effect, although the next generation ARBs could be a significant breakthrough in the field of cardiovascular medicine. 5)Azilsartan medoxomil and azilsartan have been reported to have greater antihypertensive effects than other ARBs.6-9) Azilsartan has been shown to bind tightly to and dissociate slowly from AT 1 receptors.10) Therefore, we hypothesized that the depressor effect of azilsartan may be superior to those of other ARBs in patients with hypertension (HTN). In this study, we performed a changeover from their prior ARBs to azilsartan or olmesartan in patients with hypertension, and compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. MethodsStudy design: Sixty-four hypertensive patients who were treated with ARBs except for azilsartan and olmesartan were enrolled. We applied a changeover of ARBs, where patients were prospectively and randomly switched from their prior ARBs, except for azilsartan and ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Contact Info
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Product
Resources
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.
